Merck & Co., Inc.
147.53USD
-0.9300 (-0.63%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 59.3B | 60.1B | 64.2B | 65.0B | 67.1B | 70.3B |
| Q1 | 15.9B | 14.5B | 15.8B | 15.5B | 16.3B | — |
| Q2 | 14.6B | 15.0B | 16.1B | 15.8B | 16.6B | — |
| Q3 | 15.0B | 16.0B | 16.7B | 17.3B | 17.3B | — |
| Q4 | 13.8B* | 14.6B* | 15.6B* | 16.4B* | 16.9B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 5.71 | .140 | 6.74 | 7.28 | 2.75 | 9.55 |
| Q1 | 1.70 | 1.11 | 1.87 | 2.01 | -1.72 | — |
| Q2 | 1.55 | -2.35 | 2.14 | 1.76 | -.540 | — |
| Q3 | 1.28 | 1.86 | 1.24 | 2.32 | 2.21 | — |
| Q4 | 1.19* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.481* |
| 1.47* |
| 1.18* |
| 1.96 |
| — |